- > Frequently Asked Questions (FAQ) on Mouse Models for Ophthalmic Diseases
- > Revolutionizing Neovascular Ophthalmology Research: Cyagen's Phenotypically Stable Humanized VEGF Mice
- > Vision Stolen by Years - Age-related Macular Degeneration
- > Accelerating CAR-T Cell Therapy Research
- > Preclinical Pharmacological Model of CAR T-Cell Therapy
Most Popular
|
Research Trends
|
| Spinocerebellar Ataxia Type III (SCA3) Research Model—B6-hATXN3 Mice |
| Apr 19, 2024 |
| This issue introduces the Spinocerebellar Ataxia Type III (SCA3) research mouse model—B6-hATXN3 mice (Product Number: C001398). Moreover, B6-hATXN3 mice exclusively express the human gene - unlike the common B6-TG(ATXN3-84Q) mice, which express both the human ATXN3 gene and the mouse Atxn3 gene. Read More > |
|
Research Trends
|
| Amyotrophic Lateral Sclerosis (ALS) TDP-43 Proteinopathy Research Model - B6-hTARDBP Mice |
| Apr 16, 2024 |
| This issue introduces the TDP-43 proteinopathy research model - B6-hTARDBP mice (Product Number: C001418). In amyotrophic lateral sclerosis (ALS), pathological abnormalities of TDP-43 protein are almost universally present, regardless of whether the TARDBP gene is mutated. Read More > |
|
Research Trends
|
| Suitable Preclinical Atherosclerosis Research Model: B6J-Apoe Knockout Mice |
| Apr 03, 2024 |
| In this issue, we introduce the B6J-Apoe knockout (KO) mouse model for atherosclerosis research. Atherosclerosis, a specific type of arteriosclerosis, is a chronic immune-metabolic inflammatory disease that causes the buildup of fats, cholesterol and other substances on the artery walls. Read More > |
|
Breaking News
Newsletter
|
| Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery |
| Mar 28, 2024 |
| Cyagen Biosciences (Suzhou) Inc. (“Cyagen Biosciences”) and Shanghai BaiYing Bio-Technology Co., Ltd. (“Biointron”) have signed a strategic cooperation agreement. This partnership aims to fully leverage the advantages of Cyagen Biosciences' antibody discovery platform, featuring next-generation HUGO-Ab™ Fully Humanized Antibody Mice, in combination with the strengths of Biointron's Single B Cell Screening Antibody Discovery platform for developing antigen-specific monoclonal antibodies (mAbs). Read More > |
|
Research Trends
|
| Hemophilia B Disease Model - F9 Knockout Mice |
| Mar 21, 2024 |
| In this issue, we introduce the Hemophilia B disease mouse model - F9 Knockout (KO) Mice. Hemophilia is a group of hereditary bleeding disorders characterized by a deficiency in clotting factor activity, leading to prolonged clotting time and a risk of bleeding even after minor injuries. Read More > |
|
Research Trends
|
| Searching for Better Lung Cancer Models - KS Mice |
| Mar 18, 2024 |
| In this issue, we introduce the KS mouse model of lung cancer, based on the most common cancer-associated K-Ras mutant, K-Ras(G12D). Lung cancer is the most common cancer worldwide, with over 2.2 million new cases reported globally in 2020. According to data released by the Chinese National Cancer Center, lung cancer had already become the leading cause of morbidity and mortality among all malignant tumors in China by 2015. Read More > |
|
Research Trends
|
| Beta Thalassemia Research: Hbb-bs&Hbb-bt DKO Mouse Models |
| Mar 14, 2024 |
| In this edition, we provide an overview of Beta Thalassemia (β-thalassemia), a genetic blood disorder caused by reduced or absent synthesis of the beta globin (β-globin) chain of hemoglobin, and introduce Hbb-bs&Hbb-bt DKO mice as a promising Beta-thalassemia research model for preclinical therapeutics. Beta-thalassemia is one of the global social and public health issues monitored by the World Health Organization (WHO). Read More > |
|
Research Trends
|
| Small Nucleic Acid Drug Evaluation Model for Spinal Muscular Atrophy Research - B6-hSMN2(SMA) Mice |
| Feb 29, 2024 |
| Today, we'll be introducing a model of Spinal Muscular Atrophy (SMA) - B6-hSMN2(SMA) mice. But before delving into this mouse model, let's first introduce the basic pathology of SMA. Read More > |
|
Research Trends
|
| Preclinical R&D Interest Soars as the First AAV Gene Therapy for DMD Hits $200 Million in Sales |
| Feb 22, 2024 |
| Jointly developed by Sarepta Therapeutics and Roche, ELEVIDYS is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 - 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. The United States Food and Drug Administration authorized accelerated approval for this indication based on expression of ELEVIDYS micro-dystrophin in skeletal muscle observed in patients treated with ELEVIDYS in June 2023. Read More > |
|
Research Trends
|
| Obesity Research Mice Introduction (Part 2): Non-LEP/LEPR Genetic Models |
| Feb 18, 2024 |
| In our previous article, we provided an “Introduction to Murine Models of Obesity (Part 1): LEP/LEPR Classic Pathway Model”. In this edition, we will delve into non-LEP/LEPR genetic mouse models for obesity research. Read More > |
